X-ray technology and molecular analysis tool maker Bruker BioSciences said today it priced a public offering of 10.4 million shares of its common stock at $7.10 per share. That represents a discount of 8 percent to its closing price Tuesday of $7.72 on the Nasdaq, the Associated Press reported. Bruker BioSciences said it is selling 2,200,000 shares and that 8.2 million are being sold by four selling stockholders, generating net proceeds of approximately $14.7 million to the company and $54.9 million to the selling stockholders. The company has granted the underwriters an option to purchase up to an additional 330,000 shares of common stock, and the selling stockholders have granted the underwriters an option to purchase up to an additional 1,230,000 shares of common stock to cover over-allotments, if any, which would generate additional net proceeds to the company of approximately $2.2 million and to the selling stockholders of approximately $8.3 million. Proceeds will be used for general corporate purposes, potential acquisitions and for the repayment of debt, Bruker BioSciences said. Proceeds from the sale by stockholders will not go to the company. Bear, Stearns & Co. Inc. and UBS Investment Bank are acting as joint bookrunning managers for the offering. A registration statement has been filed with the US Securities and Exchange Commission. For more information, visit: www.bruker-biosciences.com